Clinical Study Boosts Psilocybin's Therapeutic Profile for Severe Conditions

A new open-label study, led by Scott T. Aaronson, demonstrates rapid and sustained efficacy of a single 25 mg dose of COMP360 psilocybin (Compass Pathways) in significantly reducing chronic suicidal ideation and depressive symptoms for up to 12 weeks, with no serious adverse events. Published in The Journal of Clinical Psychiatry, this research expands the clinical evidence for psilocybin's therapeutic potential in high-risk populations, potentially influencing future medical and regulatory discussions around psychedelic-assisted therapies. While not a direct legislative update, this positive clinical data contributes significantly to the ongoing shift towards mainstream acceptance and potential legalization pathways for psilocybin.